Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

Description

The overall goal of this study is to promote awareness of Familial Hypercholesterolemia (FH). The investigators aim to enroll patients with suspected FH into the study and will randomize them to receive usual care or motivational interview. Primary study outcomes include knowledge of FH, as well as clinical and patient-reported outcomes. This study aims to promote optimal disease management and improve outcomes of FH patients.

Conditions

Familial Hypercholesterolemia, Cholesterol, Elevated, Genetic Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The overall goal of this study is to promote awareness of Familial Hypercholesterolemia (FH). The investigators aim to enroll patients with suspected FH into the study and will randomize them to receive usual care or motivational interview. Primary study outcomes include knowledge of FH, as well as clinical and patient-reported outcomes. This study aims to promote optimal disease management and improve outcomes of FH patients.

Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

Condition
Familial Hypercholesterolemia
Intervention / Treatment

-

Contacts and Locations

Duluth

Essentia Health, Duluth, Minnesota, United States, 55805

Duluth

St. Luke's Hospital, Duluth, Minnesota, United States, 55805

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 2-75 years
  • * patients with existing clinical diagnosis or suspected FH
  • * known genetic mutation of FH
  • * patients with an initial (pretreatment) LDL level \>190 mg/dL or total cholesterol \>300 mg/dL (age \>19 years) or LDL-c \> 160mg/dL or total cholesterol \>260 mg/dL in children age 2-19 years
  • * patients currently taking a lipid-lowering medication and have an LDL \>124 mg/dL or total cholesterol \>195 mg/dL
  • * capable of providing informed consent
  • * Patients should reside in Minnesota, Wisconsin or North Dakota.
  • * Lack of research authorization
  • * unable to provide informed consent (including non-English speaking individuals)
  • * known medical condition other than FH that is thought to contribute to hyperlipidemia (i.e., untreated hypothyroidism, nephrotic syndrome, cholestasis hypopituitarism)
  • * Pregnant women and prisoners will also be excluded.

Ages Eligible for Study

2 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Essentia Health,

Study Record Dates

2025-02